Figure 2.

(A) Dispersion of repolarization after erythromycin (E) and additional verapamil (V) administration in sham and heart failure (CHF) hearts (⋆P < 0.05, significantly different from baseline; ¥P < 0.05, significantly different from erythromycin treated sham hearts) and significant decrease after additional infusion of verapamil (^#P < 0.01, significantly different from erythromycin-treated hearts; left top, distribution of MAP catheters). (B) Transmural dispersion of repolarization after erythromycin and additional verapamil administration (⋆P < 0.05, significantly different from baseline; ¥P < 0.05, significantly different from erythromycin-treated sham hearts; ^#P < 0.01, significantly different from erythromycin-treated hearts).